GSK3B and breast cancer: Moreover, as was demonstrated in in vivo metastatic breast cancer xenograft model, fisetin reduced lung metastasis and modulated the changes in the expression of EMT molecules and PTEN/Akt/GSK-3β in a similar way as in the in vitro model [83].